According to a new report published by Introspective Market Research, titled, “Pharmacogenetic Testing Market by Technology, Application, and End User, The Global Pharmacogenetic Testing Market Size Was Valued at USD 13.20 Billion in 2023 and is Projected to Reach USD 28.95 Billion by 2032, Growing at a CAGR of 9.12%. The global pharmacogenetic testing market is experiencing significant growth as healthcare systems worldwide shift toward personalized medicine. Pharmacogenetic testing analyzes how a patient’s genetic makeup affects their response to specific drugs, enabling physicians to select the most effective medication and dosage for each individual. This innovation reduces the risk of adverse drug reactions and improves therapeutic outcomes.
The technology has proven especially beneficial in areas like oncology, psychiatry, and cardiology, where genetic differences strongly influence drug efficacy. The growing adoption of precision medicine, coupled with advancements in genomic technologies, is fueling market expansion. Furthermore, as pharmaceutical companies increasingly integrate pharmacogenetic data into drug development, the market is expected to witness substantial growth over the forecast period.
A key driver propelling the pharmacogenetic testing market is the rising demand for personalized medicine. With an increasing focus on precision healthcare, clinicians and researchers are emphasizing treatment regimens tailored to an individual’s genetic profile. This approach reduces trial-and-error in prescriptions, minimizes side effects, and enhances patient outcomes. Additionally, the growing burden of chronic diseases and the rising awareness among physicians regarding genetic testing are supporting its widespread adoption globally.
One major market opportunity lies in the integration of pharmacogenetics into electronic health records (EHRs). The combination of genetic insights with patient medical history enables clinicians to make faster and more informed decisions at the point of care. As healthcare systems worldwide move toward digital transformation, the inclusion of pharmacogenetic data in EHRs could significantly improve personalized therapy management and broaden testing adoption across developing markets.
Pharmacogenetic Testing Market, Segmentation
The Pharmacogenetic Testing Market is segmented on the basis of Technology, Application, and End User.
Technology Segment
-
The technology segment is further classified into PCR, DNA Sequencing, Microarray, and Others. Among these, the PCR segment accounted for the highest market share in 2023. PCR remains the preferred technology due to its accuracy, cost-effectiveness, and scalability. It is widely used in hospitals and diagnostic centers to identify gene variants that affect drug metabolism, enabling faster and more reliable clinical decision-making.
Application Segment
-
The application segment is further classified into Oncology, Psychiatry, Cardiology, Neurology, and Others. Among these, the Oncology segment accounted for the highest market share in 2023. The increasing prevalence of cancer and the need for targeted therapies have driven the demand for pharmacogenetic testing in oncology. By identifying specific genetic mutations, oncologists can choose more effective treatments, thereby improving survival rates and minimizing adverse effects.
Some of The Leading/Active Market Players Are:
- Myriad Genetics, Inc. (United States)
- Abbott Laboratories (United States)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Illumina, Inc. (United States)
- Thermo Fisher Scientific, Inc. (United States)
- 23andMe, Inc. (United States)
- Admera Health LLC (United States)
- OneOme LLC (United States)
- Dynamic DNA Laboratories (United States)
- OPKO Health, Inc. (United States)
- Genomic Health, Inc. (United States)
- Bio-Rad Laboratories, Inc. (United States)
- QIAGEN N.V. (Netherlands)
- Pathway Genomics (United States)
- Coriell Life Sciences (United States)
- and other active players.
Key Industry Developments
- In April 2024, Illumina, Inc. launched an advanced pharmacogenomics panel designed for clinical applications. This panel offers broader coverage of gene variants associated with drug metabolism, improving the precision of clinical testing. The product is expected to accelerate the adoption of personalized medicine practices worldwide.
- In January 2024, Myriad Genetics partnered with a leading healthcare provider network to expand access to pharmacogenetic testing across primary care practices. The collaboration aims to empower physicians with genetic insights, enabling better prescribing decisions and optimized patient care.
Key Findings of the Study
- PCR technology dominated the market in 2023.
- Oncology emerged as the leading application segment.
- North America held the largest market share due to strong healthcare infrastructure and awareness.
- Rising adoption of personalized medicine and integration of genomic data into clinical workflows drive growth.
- Increasing partnerships between diagnostic companies and healthcare providers boost market expansion.
